Patient knowledge, attitudes, and expectations of cancer immunotherapies.

Shokar, Simranjot; Buldo, Elena; Siu, Lillian L.; Hansen, Aaron Richard; Spreafico, Anna; Doi, Jeffrey; Carlsson, Lindsay; Bédard, Philippe L.

doi:10.1200/jco.2018.36.15_suppl.e18551

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This might be the result of a global increase in ICU capacity across Ontario resulting from expanded billing codes for non-vented patients; conversion of ‘step down’ units to ICUs or increased admission/discharge rates. This finding could also represent an attitude shift in short stay admissions to ICU or optimism surrounding the emergence of new immunotherapies that are associated with significant autoimmune toxicities that may require critical care admission and management [ 42 , 43 , 44 ].…”

Section: Discussionmentioning

confidence: 99%

Quality of End-of-Life Care for People with Advanced Non-Small Cell Lung Cancer in Ontario: A Population-Based Study

et al. 2021

View full text Add to dashboard Cite

Ensuring high quality end of life (EOL) care is necessary for people with advanced non-small-cell lung cancer (NSCLC), given its high incidence, mortality and symptom burden. Aggressive EOL care can adversely affect the quality of life of NSCLC patients without providing meaningful oncologic benefit. Objectives: (1) To describe EOL health services quality indicators and timing of palliative care consultation provided to patients dying of NSCLC. (2) To examine associations between aggressive and supportive care and patient, disease and treatment characteristics. Methods: This retrospective population-based cohort study describes those who died of NSCLC in Ontario, Canada from 2009–2017. Socio-demographic, patient, disease and treatment characteristics as well as EOL health service quality and use of palliative care consultation were investigated. Multivariable logistic regression models examined factors associated with receiving aggressive or supportive care. Results: Aggressive care quality indicators were present in 50.3% and supportive care indicators in 60.3% of the cohort (n = 37,203). Aggressive care indicators decreased between 2009 and 2017 (57.4% to 45.3%) and increased for supportive care (54.2% to 67.5%). Benchmarks were not met by 2017 in 3 of 4 cases. Male sex and greater comorbidity were associated with more aggressive EOL care and less supportive care. Older age was negatively associated and rurality positively associated with aggressive care. No palliative care consultation occurred in 56.0%. Conclusions: While improvements in the use of supportive rather than aggressive care were noted, established Canadian benchmarks were not met. Moreover, there is variation in EOL quality between groups and use of earlier palliative care must improve.

show abstract

Section: Discussionmentioning

confidence: 99%

Quality of End-of-Life Care for People with Advanced Non-Small Cell Lung Cancer in Ontario: A Population-Based Study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…13,14,16 The improvement in the understanding of the immune response toward cancer increased the expectancies of many patients about immunotherapy. 19 The objective of the current study was to develop a standardized survey assessing the awareness and understanding of cancer immunotherapy among HCPs in healthcare institutions in eastern Saudi Arabia. Responses to a series of questions on cancer immunotherapy were assessed from the perspectives of different HCPs.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of awareness and understanding of cancer immunotherapy among healthcare professionals in eastern Saudi Arabia

Hamad

2019

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Cancer immunotherapy is a complicated field that develops rapidly; in the past decades, immunotherapy has become the standard treatment for several cancer types. The aim of the current study was to estimate the awareness and understanding of cancer immunotherapy and associated immunological concepts among healthcare professionals (HCPs) in eastern Saudi Arabia in order to assess educational needs. Methods A cross-sectional questionnaire was conducted among multidisciplinary HCPs in healthcare institutions in eastern Saudi Arabia from April 2019 to June 2019. The survey was designed to assess the awareness and understanding of HCPs’ basic scientific knowledge of cancer immunotherapy. The data were analyzed using the Statistical Package for the Social Sciences (SPSS). Reliability was tested through Cronbach’s alpha, and a χ2 or Fisher’s exact test was used to determine the distribution of categorical variables between groups. Results The study included 360 HCPs: 43.6% physicians, 21.9% nurses, 20.8% medical laboratory scientists, and 13.6% pharmacists. Only 20.6% of the HCPs considered immunotherapy the best-known cancer therapy. The overall level of awareness of cancer immunotherapy was low (55.8%), and only 6.4% of the participants had a high knowledge rate. The majority of the respondents indicated the importance of studying the science of immunotherapy. Cronbach's alphas for the HCPs’ perceptions, self-evaluation rate, and reflection scales were 0.74, 0.90, and 0.66, respectively. Simple linear regression showed a significant relationship between reflection and self-evaluation. Conclusions A reliable and consistent study revealed a low level of awareness and understanding of immunotherapy among multidisciplinary HCPs.

show abstract

Decision-making and autonomy among participants in early-phase cancer immunotherapy trials: a qualitative study

Avery,

Bell,

Baryolay

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background Participants considering early-phase cancer clinical trials (CTs) need to understand the unique risks and benefits prior to providing informed consent. This qualitative study explored the factors that influence patients’ decisions about participating in early-phase cancer immunotherapy CTs through the ethical lens of relational autonomy. Methods Using an interpretive descriptive design, interviews were conducted with 21 adult patients with advanced cancer who had enrolled in an early-phase CT. Data was analyzed using relational autonomy ethical theory and constant comparative analysis. Results The extent to which participants perceived themselves as having a choice to participate in early-phase cancer immunotherapy CTs was a central construct. Perceptions of choice varied according to whether participants characterized their experience as an act of desperation or as an opportunity to receive a novel treatment. Intersecting psychosocial and structural factors influenced participants’ decision making about participating in early-phase cancer immunotherapy trials. These relational factors included: (1) being provided with hope; (2) having trust; (3) having the ability to withdraw; and (4) timing constraints. Conclusions Findings highlight the continuum of perceived choice that exists among patients with cancer when considering participation in early-phase cancer immunotherapy CTs. All participants were interpreted as exhibiting some degree of relational autonomy within the psychosocial and structural context of early-phase CT decision making. This study offers insights into the intersection of cancer care delivery, personal beliefs and values, and established CT processes and structures that can inform future practices and policies associated with early-phase cancer immunotherapy CTs to better support patients in making informed decisions.

show abstract

Patient knowledge, attitudes, and expectations of cancer immunotherapies.

Cited by 3 publications

References 0 publications

Quality of End-of-Life Care for People with Advanced Non-Small Cell Lung Cancer in Ontario: A Population-Based Study

Quality of End-of-Life Care for People with Advanced Non-Small Cell Lung Cancer in Ontario: A Population-Based Study

Evaluation of awareness and understanding of cancer immunotherapy among healthcare professionals in eastern Saudi Arabia

Decision-making and autonomy among participants in early-phase cancer immunotherapy trials: a qualitative study

Contact Info

Product

Resources

About